<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-93 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-93</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-93</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-f5aa4dbc2a70be9a1b87a14b1a37f7ba74c33f63</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/f5aa4dbc2a70be9a1b87a14b1a37f7ba74c33f63" target="_blank">Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer</a></p>
                <p><strong>Paper Venue:</strong> Clinical Cancer Research</p>
                <p><strong>Paper TL;DR:</strong> ROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes, and this patient showed tumor shrinkage upon treatment with crizotinib.</p>
                <p><strong>Cost:</strong> 0.023</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e93.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e93.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1 fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 gene fusions (3' ROS1 kinase domain fused to 5' partner genes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Oncogenic rearrangements that fuse the ROS1 kinase-containing 3' region to various 5' partner genes, retaining the ROS1 kinase domain and activating downstream signaling; identified in a small subset (~1–2%) of NSCLC tumors and shown to be targetable by ROS1-active kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1 gene fusion (various 5' partners; ROS1 kinase domain retained)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 (receptor tyrosine kinase); activates SHP-2, PI3K/AKT/mTOR, JAK/STAT, MAPK/ERK downstream pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>~1.2% in this TMA (5/428 evaluable); across multiple studies reported ~0.9–1.7% (~1–2% of NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>FISH break-apart screening, RT-PCR/inverse PCR and sequencing; functional cell-line studies; clinical response to targeted therapy (crizotinib)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Expression of ROS1 fusions transforms cells (IL3-independent growth in Ba/F3, transformation in NIH3T3 reported); ROS1 inhibitors reduce ROS1 autophosphorylation and downstream SHP-2, AKT and ERK signaling and inhibit proliferation in ROS1 fusion-positive cells; clinical tumor regression in a ROS1 fusion-positive patient treated with crizotinib.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected in both adenocarcinoma and squamous histologies in this cohort; observed in never-smokers and current/former smokers; present in tumors lacking EGFR/KRAS mutations (i.e., 'pan-negative' cases).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ROS1 fusions are actionable — tumors harboring ROS1 fusions can respond to ROS1-active inhibitors such as crizotinib and other ALK/ROS1 kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>TMA: 447 samples (428 evaluable); University of Colorado screening: 48 patients</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH break-apart assay, RT-PCR for known partners, inverse PCR to identify unknown partners, Sanger sequencing; phospho-RTK array and western blot for signaling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e93.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SDC4-ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SDC4 (syndecan-4) - ROS1 fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A ROS1 fusion in which SDC4 exon 2 is fused to ROS1 exon 32 (long) or exon 34 (short) generating oncogenic ROS1 fusion isoforms; identified in a University of Colorado patient and one TMA sample in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SDC4 exon2 - ROS1 exon32/34 gene fusion (SDC4-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SDC4-ROS1 fusion activates ROS1 RTK signaling (SHP-2, ERK, STAT3, AKT pathways)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Detected in 1/48 University of Colorado patients screened and in 1 TMA sample in this study; overall frequency among NSCLC is rare (part of the ~1–2% ROS1-positive subset)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Inverse PCR and RT-PCR identification and Sanger sequencing; lentiviral expression in Ba/F3 and functional assays; clinical treatment with crizotinib (patient case)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Expression of SDC4-ROS1 (long form) in Ba/F3 cells induced IL3-independent growth; increased SHP-2, ERK, and STAT3 phosphorylation in Ba/F3; the patient with SDC4-ROS1 experienced a confirmed partial response to crizotinib (57% tumor shrinkage).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>CU patient: 65-year-old male never-smoker with adenocarcinoma; tumor was wild-type for EGFR and KRAS and ALK-negative.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Responsive to crizotinib (ROS1-active kinase inhibitor) in the reported patient; ROS1 inhibition is a validated therapeutic approach for tumors harboring SDC4-ROS1.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Identified in 1 of 48 screened CU patients and 1 TMA sample (part of 5 ROS1+ in TMA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH break-apart, inverse PCR to identify partner, RT-PCR, Sanger sequencing, lentiviral expression and Ba/F3 functional assays, PET-CT clinical response assessment</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e93.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SLC34A2-ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SLC34A2 - ROS1 fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A ROS1 fusion between SLC34A2 (exon 4) and ROS1 (exons 32 and 34 yielding long and short isoforms), previously identified in the HCC78 NSCLC cell line and observed in patient tumor samples in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SLC34A2 exon4 - ROS1 exon32/34 gene fusion (SLC34A2-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SLC34A2-ROS1 activates ROS1 RTK signaling (SHP-2, PI3K/AKT/mTOR, JAK/STAT, MAPK/ERK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed in 2 TMA samples in this study and present in the HCC78 NSCLC cell line; part of the overall ~1–2% ROS1-positive NSCLC subset</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>RT-PCR and sequencing in tumors; phosphoproteomic detection in HCC78; functional studies in HCC78 cells and prior transformation assays in NIH3T3/Ba/F3 (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>HCC78 cells (SLC34A2-ROS1) show ROS1 phosphorylation; ROS1 inhibitors reduce proliferation and downstream signaling in HCC78; prior studies showed transforming capacity in model systems.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ROS1 inhibitors can suppress signaling and proliferation in SLC34A2-ROS1-expressing cells, but HCC78 exhibited reduced sensitivity compared with Ba/F3 SDC4-ROS1 models possibly due to co-activation of EGFR/MET; EGFR inhibition sensitized HCC78 to ROS1 inhibition in vitro.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Detected among TMA cohort (see overall cohort size) and present in the HCC78 cell line</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH, RT-PCR, Sanger sequencing; phospho-RTK array and western blot in HCC78</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e93.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CD74-ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CD74 - ROS1 fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A ROS1 fusion joining CD74 exon 6 to ROS1 exon 34 (short transcript) identified in patient tumor samples; previously reported in NSCLC.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CD74 exon6 - ROS1 exon34 gene fusion (CD74-ROS1, short form)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CD74-ROS1 activates ROS1 RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Detected in 2 TMA samples in this study; overall rare (part of ~1–2% ROS1+ NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>RT-PCR and sequencing in TMA samples; referenced prior reports of CD74-ROS1 in NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Prior reports and cited studies indicate transforming activity when expressed in cell models; in this study, detection by RT-PCR confirms expression.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Expected to be targetable by ROS1-active kinase inhibitors (by analogy and prior reports), though specific clinical cases in this paper refer to other ROS1 fusion partners.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Detected in 2 TMA samples within the studied cohort</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH followed by RT-PCR targeting known fusion partners and Sanger sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e93.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TPM3-ROS1 / EZR-ROS1 / LRIG3-ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>TPM3-ROS1, EZR-ROS1, LRIG3-ROS1 gene fusions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Additional ROS1 fusion partners reported in the literature and mentioned in this paper (Takeuchi et al.), indicating multiple distinct 5' partners can fuse to ROS1 in NSCLC.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TPM3-ROS1, EZR-ROS1, LRIG3-ROS1 gene fusions (various exon breakpoints reported in Takeuchi et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 gene fusions (ROS1 RTK signaling)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Reported by Takeuchi et al. among their ROS1-positive cases (Takeuchi et al. found multiple ROS1 partners among 13 ROS1+ of 1476 NSCLC samples); overall rare</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Literature report cited (Takeuchi et al.); mentioned here</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Cited studies (Takeuchi et al. and others) reported transforming activity for various ROS1 fusions in model systems.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Likely targetable by ROS1-active inhibitors based on preservation of ROS1 kinase domain and reports of sensitivity in ROS1 fusion-positive cases.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Reported in cited studies using FISH/RT-PCR and sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e93.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FIG-ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>FIG (GOPC) - ROS1 fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An intra-chromosomal deletion in chromosome 6 fusing FIG (GOPC) to ROS1; originally discovered in a glioblastoma cell line and reported in other tumor types (cholangiocarcinoma), cited here as an example of oncogenic ROS1 fusions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>FIG (GOPC) - ROS1 gene fusion (reported in glioblastoma, cholangiocarcinoma)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 RTK fusion (FIG-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Literature citation (historical discovery); mentioned for context</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Cited literature reports FIG-ROS1 is oncogenic in model systems (transformation in NIH3T3, Ba/F3, mouse models).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Demonstrates concept of ROS1 fusions as oncogenic drivers and potential therapeutic targets; specific lung clinical relevance indirect.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Reported by others using genomic breakpoint mapping and expression assays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e93.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutations / activation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor (EGFR) activating mutations and EGFR activation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>EGFR activating mutations (e.g., exon 19 deletions, L858R — referenced) are established drivers in NSCLC; this study also detected phosphorylated/activated EGFR in the HCC78 ROS1 fusion-positive cell line and used gefitinib experimentally to probe its role in ROS1 inhibitor sensitivity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR activating mutations (literature references) and EGFR phosphorylation/activation observed in HCC78</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (activating) and RTK activation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR (RTK) — canonical RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Literature mention for canonical drivers; in-study phospho-RTK array detected EGFR phosphorylation in HCC78; functional pharmacologic testing with gefitinib in vitro</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Phospho-RTK array shows high EGFR phosphorylation in HCC78 cells; gefitinib alone had no effect on proliferation but 1 µM gefitinib significantly sensitized HCC78 cells to ROS1 inhibitor NVP-TAE684 in vitro.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>EGFR mutations associated with clinical responses to gefitinib/erlotinib (discussed in intro); enriched in never-smokers (not quantitatively reported here).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>EGFR inhibitors (gefitinib/erlotinib) are effective in EGFR-mutant NSCLC; EGFR co-activation may mediate reduced sensitivity to ROS1 inhibition and combined targeting can sensitize cells in vitro.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Phospho-RTK array, western blot; literature detection of EGFR mutations by sequencing referenced</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e93.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ALK gene rearrangements (e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Established oncogenic gene fusions in NSCLC (for example EML4-ALK) that define a clinical subset treatable with ALK inhibitors; used here as comparison and because ALK inhibitors (crizotinib, NVP-TAE684) also have activity against ROS1.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ALK gene rearrangement (gene fusion such as EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK (RTK) — RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Literature mention; ALK inhibitors used experimentally as ROS1-active agents (crizotinib, NVP-TAE684)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Extensively documented in prior literature (cited); in this study EML4-ALK expressing Ba/F3 cells were used as a comparator for inhibitor sensitivity.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>ALK rearrangements define a subset responsive to crizotinib; discussed as background (no new clinicopathologic associations reported here).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ALK inhibitors (crizotinib) are clinically effective in ALK-rearranged NSCLC; these agents also inhibit ROS1 and are repurposed for ROS1 fusion-positive cases.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH/RT-PCR mentioned in the field; in this study ALK status was used as part of patient characterization (ALK-negative).</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e93.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS activating mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS activating mutations are canonical drivers in NSCLC; the CU ROS1-positive patient was wild-type for KRAS (reported), underscoring mutual exclusivity in many cases between ROS1 fusions and classical driver mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS point mutations (canonical activating mutations referenced as driver events)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS — RAS pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Mention as part of patient molecular characterization (CU patient reported wild-type for EGFR and KRAS)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>KRAS mutations are commonly assessed to define molecular subsets; no specific associations reported in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Clinical molecular testing (reported as wild-type for patient)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e93.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET activation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET receptor tyrosine kinase activation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MET phosphorylation/activation was detected in the HCC78 ROS1 fusion-positive cell line by phospho-RTK array; a MET inhibitor (PF-04217903) was tested pharmacologically but did not sensitize cells to ROS1 inhibition the way EGFR inhibition did.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET activation (phosphorylation) in HCC78 cells; no specific genomic amplification or mutation described in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>RTK activation (phosphorylation); genomic copy number not reported here</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET (RTK) — can engage PI3K/AKT and MAPK/ERK pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Phospho-RTK array detection and pharmacologic testing with MET inhibitor PF-04217903 in vitro</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Phospho-RTK array showed MET phosphorylation in HCC78; PF-04217903 alone had no effect on proliferation and did not significantly sensitize to ROS1 inhibitor, indicating MET activation may coexist but not be the primary driver in this context.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>MET inhibitors were tested but did not produce the same effects as ROS1 inhibition in HCC78; co-activation may influence response to ROS1-targeted therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Phospho-RTK array, drug-sensitivity assays (MTS)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e93.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e93.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF / PIK3CA (mentioned)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF and PIK3CA oncogenic alterations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BRAF and PIK3CA are cited as examples of other activated oncogenes found in NSCLC and that can occur across histologic subtypes; mentioned in discussion as part of the broader landscape of NSCLC drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF activating mutations and PIK3CA alterations (mentioned as other oncogenes in NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / oncogenic alteration (literature mention)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF (RAF kinase — RAS/RAF pathway), PIK3CA (PI3K pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Literature mention in discussion (not experimentally assessed in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mentioned as found in both adenocarcinoma and squamous histologies (discussion), no additional associations reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer', 'publication_date_yy_mm': '2012-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>RET, ROS1 and ALK fusions in lung cancer <em>(Rating: 2)</em></li>
                <li>ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers <em>(Rating: 2)</em></li>
                <li>Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer <em>(Rating: 2)</em></li>
                <li>Spectrum of oncogenic driver mutations in lung adenocarcinomas from East asian never smokers <em>(Rating: 2)</em></li>
                <li>Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>